Thailand vs Japan for IVF: Which is Better | Comprehensive Comparison of Technology, Laws, Costs, and Success Rates

Scenario-based opening (real consultation scenario)

No Absolute Good or Bad, Only Fit

There is no absolute superiority or inferiority between IVF in Thailand and Japan. However, the significant differences in the medical systems, legal environments, and treatment philosophies of the two countries determine that they are suitable for different populations. The following is a comparison from six core dimensions:

Differences Between the Two Countries from a Clinical Decision-Making Perspective

The difference in ovarian stimulation strategies is a direct reflection of the differing treatment philosophies between the two countries.

The mainstream approach in Japan is to start with a low dose and adjust gradually based on the patient's FSH, LH, E2 levels, and antral follicle development. Monitoring frequency is high, typically involving serum hormone tests and ultrasounds every 1-2 days during the late follicular phase. The goal is to obtain a moderate number of good-quality oocytes while reducing the risk of OHSS. This strategy is advantageous for patients with normal ovarian function, but for older patients or those with low ovarian reserve, the cycle cancellation rate can be higher.

Doctors at top-tier centers in Thailand are more flexible with stimulation protocols. For patients with low ovarian reserve, they may use protocols like PPOS, luteal phase stimulation, or dual stimulation. The core logic is to retrieve as many oocytes as possible in the shortest time, because for these patients, ovarian function is continuously declining, making time the most critical cost. The trade-off for this strategy is that follicular uniformity may not be as good as with the Japanese approach, and it requires more experienced doctors.

Legal Framework Determines Accessibility

Japan's Maternal Body Protection Act and the guidelines of the Japan Society of Obstetrics and Gynecology strictly limit assisted reproductive services to legally married couples. This means single women, same-sex couples, and families requiring egg donation, sperm donation, or gestational surrogacy cannot access these services in Japan. Additionally, foreign patients need a valid visa to travel to Japan, and some regions require notarized proof of marital relationship.

Thailand's legal framework for assisted reproduction is more open. It allows egg and sperm donation, and gestational surrogacy can be performed under statutory conditions. However, it is important to note that Thailand's relevant laws have been adjusted since 2024, with stricter regulations. It is recommended to confirm the latest policies with a local legal advisor before making arrangements. Before traveling to Thailand, ensure your passport is valid for more than 6 months and arrange a medical visa or visa on arrival (depending on the length of stay).

Hidden Differences in Embryo Culture Systems

This is the dimension with the biggest difference between the two countries but is most often overlooked.

Fertility centers in Japan generally use individualized protocols for embryo culture, adjusting the culture medium composition based on the embryo's metabolic parameters. Incubators are often time-lapse systems, combined with low oxygen environments (5% O₂), allowing real-time monitoring of embryo development. Most Japanese centers insist on single embryo transfer and have strict embryo grading standards. For luteal phase support, Japan commonly uses Crinone or oral progesterone, with relatively uniform protocols.

Laboratory equipment at top-tier centers in Thailand is equally advanced, but the culture philosophy leans more towards standardized processes. A uniform culture protocol is used for a batch of oocytes, offering advantages in batch processing efficiency. However, for patients with low ovarian reserve and few oocytes, it may lack the individualized adjustment down to each embryo that Japan offers. The strategy for using PGT is another difference: Japan strictly controls the indications for PGT, limiting it to patients with a clear risk of genetic diseases or recurrent miscarriage; Thailand is relatively more lenient, allowing its use as an embryo screening tool.

Differences in Cost Structure

Thailand's cost advantage lies not only in the absolute value but also in the flexibility of its structure.

Japan's cost breakdown includes: initial consultation fee, examination fee, ovarian stimulation medication fee (charged based on actual dosage), oocyte retrieval surgery fee, culture fee, and transfer fee. The cost of stimulation medication is the biggest variable; older patients may require higher doses, potentially doubling the medication cost. Japan's health insurance covers some examinations and basic treatments, but IVF itself is out-of-pocket. The registration fee is typically 50,000-100,000 JPY (approximately 2,500-5,000 RMB).

Thailand's cost structure is more "package-oriented," often offered as a fixed price for the entire cycle (excluding medication) or on a per-procedure basis. Medication costs are separate, but Thailand allows the use of generic drugs, making the overall medication cost 30-50% lower than in Japan. Thailand's cost advantage is mainly in medication, surgery, and culture fees. Some centers offer packages including oocyte retrieval + culture + transfer + PGT, priced between 120,000 and 180,000 RMB.

It is important to note that costs in both countries do not include embryo cryopreservation fees (usually charged annually), nor any potential additional costs for hysteroscopy or genetic counseling.

Frequently Asked Questions

Practitioner's Observation